Jin Yang Pharmaceutical Co. Ltd (KQ:007370) — Market Cap & Net Worth
Market Cap & Net Worth: Jin Yang Pharmaceutical Co. Ltd (007370)
Jin Yang Pharmaceutical Co. Ltd (KQ:007370) has a market capitalization of $36.59 Million (₩53.99 Billion) as of August 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #23006 globally and #1487 in its home market, demonstrating a -2.68% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jin Yang Pharmaceutical Co. Ltd's stock price ₩3820.00 by its total outstanding shares 14134587 (14.13 Million). See 007370 capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Jin Yang Pharmaceutical Co. Ltd Market Cap History: 2015 to 2026
Jin Yang Pharmaceutical Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $37.05 Million to $36.59 Million (-1.52% CAGR).
Index Memberships
Jin Yang Pharmaceutical Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$202.56 Billion | 0.02% | #724 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$202.56 Billion | 0.02% | #724 of 1384 |
Weight: Jin Yang Pharmaceutical Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Jin Yang Pharmaceutical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jin Yang Pharmaceutical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Jin Yang Pharmaceutical Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Jin Yang Pharmaceutical Co. Ltd's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $42.31 Million | $36.13 Billion | -$9.10 Billion | 0.00x | N/A |
| 2017 | $38.73 Million | $43.45 Billion | -$5.77 Billion | 0.00x | N/A |
| 2018 | $32.56 Million | $46.86 Billion | $933.15 Million | 0.00x | 0.03x |
| 2019 | $39.04 Million | $47.35 Billion | $1.65 Billion | 0.00x | 0.02x |
| 2020 | $63.03 Million | $48.81 Billion | $3.68 Billion | 0.00x | 0.02x |
| 2021 | $64.33 Million | $62.84 Billion | $9.54 Billion | 0.00x | 0.01x |
| 2022 | $60.94 Million | $76.26 Billion | $12.31 Billion | 0.00x | 0.00x |
| 2023 | $59.29 Million | $94.11 Billion | $12.66 Billion | 0.00x | 0.00x |
| 2024 | $55.75 Million | $113.33 Billion | $29.69 Billion | 0.00x | 0.00x |
| 2025 | $48.18 Million | $120.69 Billion | $22.29 Billion | 0.00x | 0.00x |
Competitor Companies of 007370 by Market Capitalization
Companies near Jin Yang Pharmaceutical Co. Ltd in the global market cap rankings as of August 4, 2026.
Key companies related to Jin Yang Pharmaceutical Co. Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Jin Yang Pharmaceutical Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jin Yang Pharmaceutical Co. Ltd's market cap moved from $37.05 Million to $ 36.59 Million, with a yearly change of -1.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩36.59 Million | -24.06% |
| 2025 | ₩48.18 Million | -13.57% |
| 2024 | ₩55.75 Million | -5.98% |
| 2023 | ₩59.29 Million | -2.70% |
| 2022 | ₩60.94 Million | -5.26% |
| 2021 | ₩64.33 Million | +2.06% |
| 2020 | ₩63.03 Million | +61.45% |
| 2019 | ₩39.04 Million | +19.89% |
| 2018 | ₩32.56 Million | -15.93% |
| 2017 | ₩38.73 Million | -8.46% |
| 2016 | ₩42.31 Million | +14.20% |
| 2015 | ₩37.05 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Jin Yang Pharmaceutical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.59 Million USD |
| MoneyControl | $36.59 Million USD |
| MarketWatch | $36.59 Million USD |
| marketcap.company | $36.59 Million USD |
| Reuters | $36.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jin Yang Pharmaceutical Co. Ltd
Jin Yang Pharmaceutical Co., Ltd. engages in the pharmaceutical business in South Korea. The company offers crivix tablets, Eszol tablets, atolan tablets, prescription drugs, and over-the-counter drugs. It also offers antilipidemic, antiplatelet, gastrointestinal, and respiratory agents; antithrombotics; NSAIDs; menopause symptoms treatment; and stomatological products. The company also exports i… Read more